Just a final word on your question about half life and why I think there is a threat from next generation product, here is another recent comparison between a Ga68 based product and Cu64 product. This time in Neuroendocrine tumours rather than prostate. Even regardless of when the patient was imaged, Cu64 detected about double the amount of lesions compared to Ga68. But nothing to see here, right?
”Topline results: The results indicate that lesion detection by 64Cu-SARTATE (regardless of imaging timepoint) substantially outperformed that of 68Ga-DOTATATE. 64Cu-SARTATE detected 393 to 488 lesions, and 68Ga-DOTATATE identified 186 to 265 lesions among 45 participants across the readers.”
Reference: DISCO trial headline results June 2025
TLX Price at posting:
$25.51 Sentiment: Sell Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)